

Anteo Signs Agreement With The Defence Materials Technology Centre

11 November 2016

- **Anteo becomes a Supporting Participant within the Defence Materials Technology Centre (DMTC)**
- **Anteo to benefit from DMTC support programs**

Anteo Diagnostics Limited (ASX: ADO) is pleased to announce that it has signed an Agreement to become a Supporting Participant of the DMTC.

The DMTC is a collaborative venture that drives the creation of Australian manufacturing capability in advanced materials by facilitating industry-led research and commercialisation projects. The DMTC projects target areas of Defence priority that can be readily transitioned into service in the Australian Defence Force (ADF) through commercialisation or building and enhancing defence industry capabilities.

The DMTC facilitates research into a broad range of areas including; new generation composite materials, advanced coatings and joining technologies.

Anteo Group CEO Dr. Jef Vangenechten said, "Anteo welcomes the opportunity to participate in the DMTCs proven collaborative model that brought together 41 projects delivering new technologies and manufacturing processes in FY2015."

Anteo is set to benefit from leveraging the DMTC's support across a range of Centre objectives including:

- linking Supporting Participant's to research expertise and networks;
- actively embedding Supporting Participant's into supply chains;
- participation in R&D activities which are of direct relevance to Defence; and
- cost efficient access to R&D.

"This represents the first step in moving into the Medical Countermeasures Program that is administered through the DMTC.

Ancillary benefits of participating in the DMTC is the visibility of Anteo's coating technology in other application areas and industries outside of the Medical Devices (including POC)," said Dr Vangenechten.

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 countries across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit www.anteodx.com

Media Relations relating to Mark Bouris contact Lyndsey Douglas: +61 424 203935